[go: up one dir, main page]

HK1039065B - 基於相反电荷多肽的合成剂 - Google Patents

基於相反电荷多肽的合成剂 Download PDF

Info

Publication number
HK1039065B
HK1039065B HK02100485.0A HK02100485A HK1039065B HK 1039065 B HK1039065 B HK 1039065B HK 02100485 A HK02100485 A HK 02100485A HK 1039065 B HK1039065 B HK 1039065B
Authority
HK
Hong Kong
Prior art keywords
igf
insulin
composition
arginine
formulation
Prior art date
Application number
HK02100485.0A
Other languages
German (de)
English (en)
French (fr)
Other versions
HK1039065A1 (zh
Inventor
Q. Oeswein James
R. Smikahl John
X. Wang Sharon
A. Yeung Douglas
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of HK1039065A1 publication Critical patent/HK1039065A1/zh
Publication of HK1039065B publication Critical patent/HK1039065B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/808—Optical sensing apparatus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Detergent Compositions (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Hydrogenated Pyridines (AREA)
HK02100485.0A 1999-04-08 2000-03-30 基於相反电荷多肽的合成剂 HK1039065B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12839299P 1999-04-08 1999-04-08
US128392 1999-04-08
PCT/US2000/008682 WO2000061177A1 (en) 1999-04-08 2000-03-30 Composition based on oppositely-charged polypeptides

Publications (2)

Publication Number Publication Date
HK1039065A1 HK1039065A1 (zh) 2002-04-12
HK1039065B true HK1039065B (zh) 2004-04-16

Family

ID=22435148

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02100485.0A HK1039065B (zh) 1999-04-08 2000-03-30 基於相反电荷多肽的合成剂

Country Status (13)

Country Link
US (2) US6559122B1 (zh)
EP (1) EP1165119B1 (zh)
JP (2) JP4360758B2 (zh)
AT (1) ATE251466T1 (zh)
AU (1) AU763039B2 (zh)
CA (1) CA2369451C (zh)
DE (1) DE60005806T2 (zh)
DK (1) DK1165119T3 (zh)
ES (1) ES2208305T3 (zh)
HK (1) HK1039065B (zh)
IL (1) IL145597A0 (zh)
PT (1) PT1165119E (zh)
WO (1) WO2000061177A1 (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
DE60005806T2 (de) * 1999-04-08 2004-08-05 Genentech, Inc., South San Francisco Zusammensetzung auf basis gegensätzlich geladener polypeptide
JP2003528149A (ja) * 2000-03-24 2003-09-24 ジェネンテック・インコーポレーテッド 軟骨性疾患の治療のためのインスリンの使用
PT1478394E (pt) 2002-02-27 2008-10-08 Immunex Corp Composição estabilizada compreendendo tnfr - fc e arginina
US7655619B2 (en) 2002-05-06 2010-02-02 Thomas Jefferson University Insulin-associated peptides with effects on cerebral health
JP2006514990A (ja) * 2002-12-27 2006-05-18 ディオベックス， インコーポレイテッド インスリン誘発性低血糖の予防および制御のための組成物および方法
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
KR20070010115A (ko) * 2003-11-13 2007-01-22 알자 코포레이션 경피전달용 조성물 및 장치
CA2558911C (en) * 2004-03-11 2016-12-06 Genentech, Inc. Process for producing polypeptides
DK2708225T3 (en) 2004-04-23 2019-04-08 Cydex Pharmaceuticals Inc DPI formulation containing sulfoalkyl ether cyclodextrin
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc SELF-BUFFING PROTEIN FORMULATIONS
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
WO2008025527A1 (en) * 2006-08-31 2008-03-06 F. Hoffmann-La Roche Ag Method for the production of insulin-like growth factor-i
US20110045510A1 (en) * 2008-04-03 2011-02-24 Kurt Lang Pegylated insulin-like-growth-factor assay
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
US20110207764A1 (en) * 2010-02-23 2011-08-25 Valery Alakhov Cyclopolysaccharide compositions
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
WO2014151725A1 (en) * 2013-03-14 2014-09-25 Allergan, Inc. Composition of a sustained-release delivery and method of stabilizing proteins during fabrication process
KR102446838B1 (ko) 2016-10-21 2022-09-26 암젠 인크 약학적 제형 및 그의 제조 방법

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0561137B1 (en) 1983-04-25 2002-07-03 Chiron Corporation Hybrid DNA Synthesis of Mature Insulin-like Growth Factors
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
DE3326473A1 (de) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
JPH0720993B2 (ja) 1985-08-22 1995-03-08 グロペップ プロプライエタリー リミテッド 生長因子
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
AU607209B2 (en) 1987-04-23 1991-02-28 Monsanto Technology Llc Secretion of insulin-like growth factor-i in e. coli
US4876242A (en) 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
JPH0788395B2 (ja) 1987-10-23 1995-09-27 シェリング・コーポレーション タンパク質の精製方法
WO1989005822A1 (en) 1987-12-24 1989-06-29 Gropep Pty. Ltd. Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
US5470828A (en) 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
US4988675A (en) 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
US5091173A (en) 1989-06-29 1992-02-25 The University Of Dundee Hair growth composition
GB8920381D0 (en) 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
JPH0818999B2 (ja) 1990-01-05 1996-02-28 藤沢薬品工業株式会社 インシュリン様成長因子ｉの乾燥製剤
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5374620A (en) 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
CA2125284C (en) 1991-12-05 2000-06-20 Jens-Christian Wunderlich Peroral administration form for peptidic medicaments, in particular insulin
US5614219A (en) 1991-12-05 1997-03-25 Alfatec-Pharma Gmbh Oral administration form for peptide pharmaceutical substances, in particular insulin
SE9201573D0 (sv) 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
SE9300105D0 (sv) 1993-01-15 1993-01-15 Kabi Pharmacia Ab Stable protein solution
EP0642350A4 (en) 1993-01-25 1995-06-28 Beth Israel Hospital METHOD FOR MODIFYING, DIAGNOSING AND DETECTING IGF-1 SENSITIVE CELL BARRIER PROPERTIES.
SE9402119D0 (sv) 1994-06-16 1994-06-16 Pharmacia Ab Solution
SE9402331D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab New use
SE9402370D0 (sv) 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5788959A (en) 1995-04-24 1998-08-04 University Of Maryland, Baltimore County Drug delivery device and method for employing the same
ES2175433T3 (es) 1996-07-10 2002-11-16 West Pharm Serv Drug Res Ltd Composiciones indicadas para la administracion de genes en celulas epiteliales.
US5783556A (en) 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
CO4750643A1 (es) 1997-06-13 1999-03-31 Lilly Co Eli Formulacion estable de la insulina que contiene l-arginina y protamina
EP1028748B1 (en) * 1997-11-07 2003-05-02 Chiron Corporation Compositions providing for increased igf-i solubility
DE60005806T2 (de) * 1999-04-08 2004-08-05 Genentech, Inc., South San Francisco Zusammensetzung auf basis gegensätzlich geladener polypeptide

Also Published As

Publication number Publication date
US20030195142A1 (en) 2003-10-16
HK1039065A1 (zh) 2002-04-12
WO2000061177A1 (en) 2000-10-19
US6559122B1 (en) 2003-05-06
ES2208305T3 (es) 2004-06-16
EP1165119B1 (en) 2003-10-08
DK1165119T3 (da) 2003-12-15
DE60005806T2 (de) 2004-08-05
ATE251466T1 (de) 2003-10-15
JP2002541212A (ja) 2002-12-03
PT1165119E (pt) 2004-02-27
US7186686B2 (en) 2007-03-06
JP4360758B2 (ja) 2009-11-11
CA2369451A1 (en) 2000-10-19
EP1165119A1 (en) 2002-01-02
AU4061300A (en) 2000-11-14
AU763039B2 (en) 2003-07-10
WO2000061177A9 (en) 2002-04-18
IL145597A0 (en) 2002-06-30
CA2369451C (en) 2009-09-22
JP2009029803A (ja) 2009-02-12
DE60005806D1 (de) 2003-11-13

Similar Documents

Publication Publication Date Title
EP1165119B1 (en) Composition based on oppositely-charged polypeptides
JP4187075B2 (ja) 製剤
US6410511B2 (en) Formulations for amylin agonist peptides
US5374620A (en) Growth-promoting composition and its use
AU760609B2 (en) Formulations for amylin agonist peptides
US7312196B2 (en) Formulations for amylin agonist peptides
US5597802A (en) Method of formulating IGF-I with growth hormone
US20050176621A1 (en) Crystalline compositions for controlling blood glucose
US20050054818A1 (en) Crystalline compositions for controlling blood glucose
AU752411B2 (en) Formulation

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190330